{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:47:56Z","timestamp":1790542076124,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007077","name":"National Institute of Biomedical Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.bbrc.2009.04.136","type":"journal-article","created":{"date-parts":[[2009,5,6]],"date-time":"2009-05-06T04:23:35Z","timestamp":1241583815000},"page":"471-475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":150,"title":["The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential"],"prefix":"10.1016","volume":"384","author":[{"given":"Hiroyuki","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Inoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohsuke","family":"Masutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Komai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Liang","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2009.04.136_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(98)01346-4","article-title":"Pathogenesis, prevention, and treatment of diabetic nephropathy","volume":"352","author":"Cooper","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2009.04.136_bib2","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2009.04.136_bib3","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.2337\/diab.43.11.1358","article-title":"Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria","volume":"43","author":"Fioretto","year":"1994","journal-title":"Diabetes"},{"key":"10.1016\/j.bbrc.2009.04.136_bib4","doi-asserted-by":"crossref","first-page":"506","DOI":"10.2337\/diabetes.51.2.506","article-title":"Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes","volume":"51","author":"Caramori","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.bbrc.2009.04.136_bib5","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1210\/er.2003-0018","article-title":"From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors\/cytokines","volume":"25","author":"Schrijvers","year":"2004","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bbrc.2009.04.136_bib6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2337\/db08-1328","article-title":"Enhanced expression of JAK-STAT pathway members in human diabetic nephropathy","volume":"58","author":"Berthier","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.bbrc.2009.04.136_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drudis.2006.12.008","article-title":"Targeting mammalian target of rapamycin (mTOR) for health and diseases","volume":"12","author":"Tsang","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbrc.2009.04.136_bib8","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1038\/sj.onc.1204091","article-title":"The rapamycin-sensitive signal transduction pathway as a target for cancer therapy","volume":"19","author":"Hidalgo","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2009.04.136_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1463-1326.2008.00952.x","article-title":"The role of mTOR in the adaptation and failure of beta-cells in type 2 diabetes","volume":"10","author":"Leibowitz","year":"2008","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bbrc.2009.04.136_bib10","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2353\/ajpath.2007.070412","article-title":"Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin","volume":"171","author":"Sataranatarajan","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbrc.2009.04.136_bib11","first-page":"1237","article-title":"Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture","volume":"152","author":"Nakao","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbrc.2009.04.136_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2443.2007.01044.x","article-title":"The dual function of hepatic SOCS3 in insulin resistance in vivo","volume":"12","author":"Torisu","year":"2007","journal-title":"Genes Cells"},{"key":"10.1016\/j.bbrc.2009.04.136_bib13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2337\/diab.30.2.106","article-title":"Prevention of diabetic nephropathy by diet control in the db\/db mouse","volume":"30","author":"Lee","year":"1981","journal-title":"Diabetes"},{"key":"10.1016\/j.bbrc.2009.04.136_bib14","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1101\/gad.995802","article-title":"Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1\/eIF4E","volume":"16","author":"Fingar","year":"2002","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbrc.2009.04.136_bib15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature02369","article-title":"Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy","volume":"428","author":"Wendel","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2009.04.136_bib16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.molcel.2003.08.016","article-title":"Integration of growth factor and nutrient signaling: implications for cancer biology","volume":"12","author":"Shamji","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbrc.2009.04.136_bib17","doi-asserted-by":"crossref","first-page":"187S","DOI":"10.1016\/S0041-1345(03)00228-8","article-title":"Sirolimus and islet transplants","volume":"35","author":"Hering","year":"2003","journal-title":"Transplant. Proc."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X09008730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X09008730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T10:43:06Z","timestamp":1757760186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X09008730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0006291X09008730"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2009.04.136","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2009.04.136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}